Last reviewed · How we verify
INFLUENZA G1 mHA
INFLUENZA G1 mHA is a Biologic drug developed by Janssen Vaccines & Prevention B.V.. It is currently in Phase 1 development.
At a glance
| Generic name | INFLUENZA G1 mHA |
|---|---|
| Sponsor | Janssen Vaccines & Prevention B.V. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INFLUENZA G1 mHA CI brief — competitive landscape report
- INFLUENZA G1 mHA updates RSS · CI watch RSS
- Janssen Vaccines & Prevention B.V. portfolio CI
Frequently asked questions about INFLUENZA G1 mHA
What is INFLUENZA G1 mHA?
INFLUENZA G1 mHA is a Biologic drug developed by Janssen Vaccines & Prevention B.V..
Who makes INFLUENZA G1 mHA?
INFLUENZA G1 mHA is developed by Janssen Vaccines & Prevention B.V. (see full Janssen Vaccines & Prevention B.V. pipeline at /company/janssen-vaccines-prevention-b-v).
What development phase is INFLUENZA G1 mHA in?
INFLUENZA G1 mHA is in Phase 1.
Related
- Manufacturer: Janssen Vaccines & Prevention B.V. — full pipeline